Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.
Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference
Cerebral embolic protection devices are proven to work. However, according to one cardiologist, they are still not consistently reducing stroke rates.
Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
TTVR with Evoque system linked to positive real-world outcomes after 30 days
According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.
A closer look at world’s first TAVR patient treated with new cerebral embolic protection device
The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

Cardiovascular societies support Medicare coverage for renal denervation

CMS is expected to release a proposed national coverage determination decision memo by July.

Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Getinge ending production of cardiopulmonary surgical perfusion systems

The global medtech company is also looking to expand its organ transplant and ECMO portfolios.

CABG coronary artery bypass grafting heart surgery

CABG still the ‘gold standard’ for revascularization in patients with 3-vessel CAD and CKD

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI.

Veterans with heart disease often receive better care through VA than they would elsewhere

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

healthcare value value-based care money dollar

CABG, TAVR top list of most lucrative heart procedures for hospitals

Other procedures are associated with higher profits—heart transplants, for instance—but CABG and TAVR are performed much more often.

Cardiologists recommend AVR for asymptomatic severe AS—TAVR and surgery both viable options

A trio of leading voices in cardiology reviewed years of data while considering their proposal. The choice between TAVR and SAVR, they added, should be made on a case-by-case basis.

Johnson & Johnson MedTech has launched a new next-generation catheter to be used when treating acute ischemic stroke patients. The Cereglide 92 Catheter System includes a 0.92” catheter as well as the company’s Innerglide 9 deliver aid.

Johnson & Johnson MedTech launches new large-bore catheter system for stroke

The next-generation catheter was designed to help clinicians restore blood flow safely and effectively after patients have experienced an acute ischemic stroke.

Interventional Cardiology

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving

Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

TTVR with Evoque system linked to positive real-world outcomes after 30 days

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device